Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal worth as much as $2 billion. The pact is with Adaptive Biotechnologies and ...
SAN DIEGO, CA—Aviv Regev, PhD, head and executive vice president of Research and Early Development at Genentech, kicked off the Opening Plenary Session at the American Association for Cancer Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results